A1183: Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS

Prof. B. (Bertrand) Tombal

Tombal B.¹, Saad F.², Fizazi K.³, Sternberg C.N.⁴, Crawford E.D.⁵, Gratzke C.⁶, Grabbert M.⁶, Vilaseca A.⁷, Shore N.⁸, Kopyltsov E.⁹, Bögemann M.¹⁰, Kapur S.¹¹, Srinivasan S.¹², Verholen F.¹³, Kuss I.¹⁴, Joensuu H.¹⁵, Smith M.R.¹⁶, Hussain M.¹⁷

¹Cliniques Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium, ²University of Montreal Hospital Center, Dept. of Urology, Montreal, Canada, ³University of Paris-Saclay, Institut Gustave Roussy, Villejuif, France, ⁴Englander Institute for Precision Medicine, Weill Cornell Dept. of Medicine, New York, United States of America, ⁵UC San Diego School of Medicine, Dept. of Urology, San Diego, United States of America, ⁶University Hospital Freiburg, Dept. of Urology, Freiburg, Germany, ⁷Hospital Clínic de Barcelona, Uro-oncology Unit, Barcelona, Spain, ⁸Carolina Urologic Research Center, Genesis Care, Dept. of Urology, Myrtle Beach, United States of America, ⁹Clinical Oncological Dispensary of Omsk Region, Dept. of Oncology, Omsk, Russia, ¹⁰Münster University Medical Center, Dept. of Urology, Münster, Germany, ¹¹Bayer SAE, Dept. of Medical Affairs, Singapore, Singapore, ¹²Bayer HealthCare Pharmaceuticals Inc, Dept. of Statistics, Whippany, United States of America, ¹³Bayer Consumer Care AG, Dept. of Medical Affairs, Basel, Switzerland, ¹⁴Bayer AG, Clinical Development, Berlin, Germany, ¹⁵Orion Corporation, Clinical Development, Espoo, Finland, ¹⁶Massachusetts General Hospital Cancer Center, Dept. of Hematology, Dept. of Oncology, Boston, United States of America, ¹⁷Northwestern University, Feinberg School of Medicine, Chicago, United States of America